Aakaar Medical

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.

Which are the latest news on Aakaar Medical?

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 10-Apr, Aakaar Medical Technologies Ltd's stock price is rising to 57.15, reflecting a 4.67% increase due to strong sector performance and increased investor participation. While the stock shows positive short-term momentum, it remains below its longer-term moving averages.

As of 10-Apr, Aakaar Medical Technologies Ltd's stock price is rising, currently at 57.15, reflecting a change of 2.55 or 4.67% increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.38%, indicating strong relative performance compared to its peers. Additionally, there has been a notable increase in investor participation, with a delivery volume of 4.8k on April 9, which has risen by 7.14% against the 5-day average delivery volume. This suggests growing interest and confidence among investors in the stock.<BR><BR>Moreover, the stock's current price is higher than its 5-day, 20-day, and 50-day moving averages, which typically signals positive momentum. However, it is important to note that the stock remains below its 100-day and 200-day moving averages, indicating that while there is short-term strength, longer-term trends may still be under pressure. Overall, the combination of strong sector performance, increased investor activity, and favorable short-term moving averages contributes to the rise in Aakaar Medical Technologies Ltd's stock price.